Premium
Promising immunotherapy: Highlighting cytokine‐induced killer cells
Author(s) -
Shirjang Solmaz,
Alizadeh Nazila,
Mansoori Behzad,
Mahmoodpoor Ata,
Kafil Hossein Samadi,
HojjatFarsangi Mohammad,
Yousefi Mehdi
Publication year - 2019
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.28250
Subject(s) - immunotherapy , medicine , clinical trial , cytokine induced killer cell , cancer immunotherapy , cell therapy , immune system , cancer , cytokine , immunology , cell , biology , cd8 , genetics , cd3
For many years, cancer therapy has appeared to be a challenging issue for researchers and physicians. By the introduction of novel methods in immunotherapy, the prospect of cancer therapy even more explained than before. Cytokine‐induced killer (CIK) cell‐based immunotherapy demonstrated to have potentiality in improving clinical outcomes and relieving major side effects of standard treatment options. In addition, given the distinctive features such as high safety, low toxicity effects on healthy cells, numerous clinical trials conducted on CIK cells. Due to the shortcomings that observed in CIK cell immunotherapy alone, arising a tendency to make modifications (combined modality therapy or combination therapy) including the addition of various types of cytokines, genetic engineering, combination with immune checkpoints, and so on. In this review, we have tried to bring forth the latest immunotherapy methods and their overview. We have discussed the combination therapies with CIK cells and the conducted clinical trials. This helps the future studies to use integrated therapies with CIK cells as a promising treatment of many types of cancers.